Veradermics (MANE) Accumulated Expenses (2024 - 2026)

Veradermics (MANE) has 3 years of Accumulated Expenses data on file, last reported at $5.6 million in Q1 2026.

• Quarterly Accumulated Expenses changed N/A year-over-year to $5.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.6 million (changed N/A YoY) and the FY2025 annual result came in at $7.0 million, up 182.55% from the prior year.
• Accumulated Expenses retreated to $5.6 million in Q1 2026, from $7.0 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $7.0 million in Q4 2025 to a low of $2.5 million in Q4 2024.
• A 3-year average of $5.0 million and a median of $5.6 million in 2026 frame the typical range for Accumulated Expenses.
• The widest YoY moves for Accumulated Expenses: up 182.55% in 2025, down 182.55% in 2025.
• Tracing MANE's Accumulated Expenses over 3 years: stood at $2.5 million in 2024, then surged by 182.55% to $7.0 million in 2025, then fell by 19.67% to $5.6 million in 2026.
• The last three Accumulated Expenses figures came in at $5.6 million (Q1 2026), $7.0 million (Q4 2025), and $2.5 million (Q4 2024), per Business Quant data.